Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has priced its initial public offering of 10 million shares at $15.00 each, aiming for gross proceeds of approximately $150 million. The underwriters have a 30-day option for an additional 1.5 million shares. The common stock will commence trading on Nasdaq on October 16, 2020, with the offering expected to close on October 20, 2020, pending customary conditions. J.P. Morgan, Jefferies, and Piper Sandler are managing the offering.